Skip to Content

Join the 'Gonadorelin' group to help and get support from people like you.

Gonadorelin News

Some Prostate Cancer Patients May Not Benefit From Hormone Therapy

Posted 22 Sep 2015 by Drugs.com

TUESDAY, Sept. 22, 2015 – Men with prostate cancer who also have had a heart attack may fare better with radiation therapy alone rather than with the standard treatment of radiation plus hormone therapy, a new analysis suggests. Over an average of 17 years of follow-up, men with high-risk prostate cancer who also had a heart condition lived longer after radiation treatment alone than similar men who had radiation and hormone therapy. Men who didn't have heart problems lived longer if they had both treatments, the researchers added. "There have been several trials looking at radiation with or without hormone therapy in high-risk prostate cancer which found a survival benefit from combined treatment," said lead researcher Dr. Anthony D'Amico, chief of radiation oncology at Brigham and Women's Hospital in Boston. However, whether hormone therapy causes an increase in death from heart ... Read more

Related support groups: Heart Attack, Testosterone, Lupron, Prostate Cancer, AndroGel, Testim, Lupron Depot, Axiron, Myocardial Infarction, Zoladex, Androderm, Lupron Depot 3.75 mg, Eligard, Depo-Testosterone, Fortesta, Testopel, Leuprolide, Lupron Depot-PED, Methyltestosterone, Testopel Pellets

Too Few Prostate Cancer Patients Get Bone-Strengthening Meds: Study

Posted 3 Dec 2014 by Drugs.com

TUESDAY, Dec. 2, 2014 – Many men on hormone therapy for prostate cancer aren't getting bone-strengthening drugs they may need, new Canadian research contends. Hormone therapy, which suppresses male hormones called androgens, helps stop cancer cells from growing. But one consequence of the treatment is weakening of the bones, which can lead to fractures. To reduce this risk, men can be given oral bisphosphonates, such as Fosamax, or an intravenous treatment once a month or once a year with similar drugs, such as Reclast. "There seems to be a clear mismatch between Canadian guidelines regarding bisphosphonate usage in men undergoing hormone therapy for prostate cancer and actual clinical practice," said lead researcher Dr. Shabbir Alibhai, a senior scientist at the University Health Network in Toronto. While the low rates of bisphosphonate prescriptions may be appropriate for patients ... Read more

Related support groups: Provera, Depo-Provera, Accutane, Lupron, Prostate Cancer, Tamoxifen, Medroxyprogesterone, Fosamax, Arimidex, Tretinoin, Femara, Lupron Depot, Boniva, Isotretinoin, Alendronate, Claravis, Anastrozole, Reclast, Actonel, Evista

Extended Hormone Therapy Doesn't Help Some Prostate Cancer Patients: Study

Posted 23 Sep 2013 by Drugs.com

MONDAY, Sept. 23 – For men with intermediate-risk prostate cancer, long-term hormone therapy after radiation therapy provides no survival advantages compared with short-term hormone therapy, according to a new study. Hormone therapy is used to reduce the levels of male hormones (androgens) such as testosterone, which can stimulate the growth of prostate cancer cells. Researchers examined data from 133 men with intermediate-risk prostate cancer who underwent either long-term hormone therapy (59 patients) or short-term hormone therapy (74 patients) after receiving external beam radiation therapy. Ten-year overall survival was 61 percent in the short-term group and 65 percent in the long-term group, which is not a statistically significant difference. Disease-specific survival was 96 percent in both groups. The study was scheduled for presentation Monday at the annual meeting of the ... Read more

Related support groups: Lupron, Prostate Cancer, Lupron Depot, Zoladex, Eligard, Lupron Depot 3.75 mg, Lupron Depot-PED, Leuprolide, Degarelix, Firmagon, Trelstar, Supprelin, Synarel, Trelstar LA, Goserelin, Vantas, Supprelin LA, Trelstar Depot, Lupron Depot-Gyn, Cetrotide

Kidney Failure a Possible Risk of Prostate Cancer Hormone Treatment: Study

Posted 18 Jul 2013 by Drugs.com

TUESDAY, July 16 – Hormone therapy for prostate cancer may dramatically increase a man's risk of kidney failure, according to a new study. Use of androgen deprivation therapy was tied to a 250 percent increase in a man's chances of suffering acute kidney injury, Canadian researchers found in a review of more than 10,000 men receiving treatment for early stage prostate cancer. The study appears in the July 17 issue of the Journal of the American Medical Association. Androgen deprivation therapy uses medication or surgery to reduce the amount of male hormones in a man's body, which can then cause prostate cancer cells to shrink or grow more slowly. It is a therapy usually reserved for advanced cases of prostate cancer, said study co-author Laurent Azoulay, a pharmacoepidemiologist at Jewish General Hospital's Lady Davis Institute, in Montreal. Previous research already has linked ... Read more

Related support groups: Lupron, Prostate Cancer, Lupron Depot, Zoladex, Eligard, Lupron Depot 3.75 mg, Lupron Depot-PED, Leuprolide, Degarelix, Firmagon, Trelstar, Supprelin, Synarel, Trelstar LA, Goserelin, Vantas, Supprelin LA, Trelstar Depot, Lupron Depot-Gyn, Cetrotide

Could a Prostate Cancer Treatment Raise Colon Cancer Risk?

Posted 11 Nov 2010 by Drugs.com

WEDNESDAY, Nov. 10 – Men taking hormone therapy for prostate cancer may have a slightly increased risk of developing colorectal cancer, a new study suggests. Androgen deprivation therapy is often prescribed to treat prostate cancer. But its use in treating low-risk cancer is controversial, because two potential side effects, diabetes and obesity, are risk factors for colorectal cancer, the researchers say. "We found that the use of androgen deprivation therapy, either through injections or through surgical castration, for prostate cancer was associated with a 30 to 40 percent increase in risk for colorectal cancer," said lead researcher Dr. Vahakn B. Shahinian, an assistant professor of internal medicine at the University of Michigan. As experts debate whether routine prostate-specific antigen (PSA) testing causes many men to undergo unneeded treatment for prostate cancer, this finding ... Read more

Related support groups: Lupron, Prostate Cancer, Lupron Depot, Colorectal Cancer, Zoladex, Eligard, Lupron Depot 3.75 mg, Leuprolide, Lupron Depot-PED, Supprelin, Trelstar, Synarel, Goserelin, Trelstar LA, Vantas, Lupron Depot-Gyn, Supprelin LA, Trelstar Depot, Lupron Depot 11.25 mg, Viadur

Fracture Risk Seen With Hormone Therapy for Prostate Cancer

Posted 10 Nov 2010 by Drugs.com

TUESDAY, Nov. 9 – Long-term use of androgen deprivation therapy to treat prostate cancer may increase older patients' risk of broken bones, according to a new study. These findings suggest that careful consideration is needed before doctors decide to use this therapy in older men with localized disease, the researchers said. They analyzed data from more than 46,500 men, aged 66 and older, who survived at least five years after a diagnosis of localized prostate cancer and received long-term androgen deprivation therapy. Older men with co-existing health problems are usually prescribed androgen deprivation therapy because they are not suitable candidates for radiation therapy or surgery to remove the prostate. But this study found that men treated with androgen deprivation therapy had a 20 percent increased risk of a first fracture and a 57 percent increased risk of a second fracture ... Read more

Related support groups: Lupron, Prostate Cancer, Lupron Depot, Zoladex, Eligard, Lupron Depot 3.75 mg, Leuprolide, Lupron Depot-PED, Supprelin, Synarel, Trelstar, Trelstar LA, Goserelin, Vantas, Lupron Depot-Gyn, Supprelin LA, Trelstar Depot, Lupron Depot 11.25 mg, Viadur, Triptorelin

FDA: Include Warnings on Risk for Class of Prostate Cancer Drugs

Posted 22 Oct 2010 by Drugs.com

ROCKVILLE, Md., Oct. 20, 2010--The U.S. Food and Drug Administration today asked manufacturers to add new warnings to labeling of gonadotropin-releasing hormone (GnRH) agonists, a class of drugs primarily used to treat men with prostate cancer. The warnings would alert patients and their health care professionals to the potential risk of heart disease and diabetes in men treated with these medications.  In May, the FDA said that a preliminary and ongoing analysis found that patients receiving GnRH agonists were at a small increased risk for diabetes, heart attack, stroke, and sudden death. The new labels will include updates in the Warnings and Precautions section about these potential risks. Prostate cancer is the second most common type of cancer among men in the United States, behind skin cancer, and usually occurs in older men. This year an estimated 217,730 new cases of prostate ... Read more

Related support groups: Lupron, Lupron Depot, Zoladex, Eligard, Lupron Depot 3.75 mg, Leuprolide, Lupron Depot-PED, Supprelin, Synarel, Trelstar, Goserelin, Trelstar LA, Vantas, Lupron Depot-Gyn, Supprelin LA, Trelstar Depot, Lupron Depot 11.25 mg, Triptorelin, Viadur, Lutrepulse

FDA MedWatch - GnRH Agonists: Label Change - Increased Risk of Diabetes and Cardiovascular Disease (Update)

Posted 21 Oct 2010 by Drugs.com

AUDIENCE: Oncology, Endocrine, Cardiovascular ISSUE: Gonadotropin-Releasing Hormone (GnRH) agonists will have new safety information added to the Warnings and Precautions section of the drug labels. This new information warns about increased risk of diabetes and certain cardiovascular diseases (heart attack, sudden cardiac death, stroke) in men receiving these medications for the treatment of prostate cancer. BACKGROUND: GnRH agonists are approved to treat the symptoms (palliative treatment) of advanced prostate cancer. The benefits of GnRH agonist use for earlier stages of prostate cancer that have not spread (non-metastatic prostate cancer) have not been established. FDA’s notification to manufacturers of GnRH agonists to add this safety information is based on the Agency’s review of several published studies. Most of the studies reviewed by FDA reported small but statistically sig ... Read more

Related support groups: Lupron, Lupron Depot, Zoladex, Eligard, Lupron Depot 3.75 mg, Leuprolide, Lupron Depot-PED, Supprelin, Synarel, Trelstar, Goserelin, Trelstar LA, Vantas, Lupron Depot-Gyn, Supprelin LA, Trelstar Depot, Lupron Depot 11.25 mg, Triptorelin, Viadur, Lutrepulse

FDA Calls for New Warnings on Some Prostate Cancer Drugs

Posted 20 Oct 2010 by Drugs.com

WEDNESDAY, Oct. 20 – The U.S. Food and Drug Administration on Wednesday called for new warnings on the labels of widely used hormonal prostate cancer drugs because of evidence of a slight increased risk of heart disease and diabetes in the men who take them. The FDA first announced in May that it was reviewing the prostate cancer drugs known as gonadotropin-releasing hormone (GnRH) agonists, citing this possible increased risk. These medications suppress the production of testosterone, a hormone that can spur the growth of prostate cancer. The drugs include Eligard, Lupron, Synarel, Trelstar, Vantas, Viadur, Zoladex and several generic products. Hormone-based therapy is not a cure for prostate cancer, because tumors can eventually become resistant to the therapy. However, the therapy can extend survival. So, should the new label warnings deter men from enrolling on hormone-based ... Read more

Related support groups: Lupron, Prostate Cancer, Lupron Depot, Zoladex, Eligard, Lupron Depot 3.75 mg, Leuprolide, Lupron Depot-PED, Supprelin, Synarel, Trelstar, Trelstar LA, Goserelin, Vantas, Lupron Depot-Gyn, Supprelin LA, Trelstar Depot, Lupron Depot 11.25 mg, Viadur, Triptorelin

As FDA Eyes Prostate Cancer Drugs, Experts Urge Caution

Posted 4 May 2010 by Drugs.com

TUESDAY, May 4 – When the U.S. Food and Drug Administration announced Monday it was investigating possible links between widely used hormonal prostate cancer drugs and an slight rise in risk for diabetes and heart disease, thousands of men who rely on these drugs to extend their lives were left wondering what to do next. According to experts, the main advice to those men at the moment is to keep taking the drugs, but use them with caution. The FDA says it will review a widely used class of prostate cancer drugs called gonadotropin-releasing hormone (GnRH) agonists. These include medications such as Eligard, Lupron, Synarel, Trelstar, Vantas, Viadur, Zoladex and several generic products. All of these drugs suppress the production of testosterone, a hormone thought to help spur the growth of prostate cancer. Hormone-based therapy is not a cure for prostate cancer, because tumors can ... Read more

Related support groups: Lupron, Lupron Depot, Zoladex, Eligard, Lupron Depot 3.75 mg, Leuprolide, Lupron Depot-PED, Supprelin, Synarel, Goserelin, Trelstar LA, Vantas, Lupron Depot-Gyn, Supprelin LA, Trelstar Depot, Lupron Depot 11.25 mg, Triptorelin, Viadur, Lutrepulse, Factrel

Ask a Question

Further Information

Related Condition Support Groups

Gonadotropin Deficiency, Amenorrhea

Related Drug Support Groups

Lutrepulse, Factrel

Gonadorelin Patient Information at Drugs.com